These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 974262

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hemoglobin Sendagi (beta 42 Phe----Val): a new unstable hemoglobin variant having an amino acid substitution at CD1 of the beta-chain.
    Ogata K, Ito T, Okazaki T, Dan K, Nomura T, Nozawa Y, Kajita A.
    Hemoglobin; 1986; 10(5):469-81. PubMed ID: 3781864
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hemoglobin Abraham Lincoln, beta32 (B14) leucine leads to proline. An unstable variant producing severe hemolytic disease.
    Honig GR, Green D, Shamsuddin M, Vida LN, Mason RG, Gnarra DJ, Maurer HS.
    J Clin Invest; 1973 Jul; 52(7):1746-55. PubMed ID: 4352462
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Unique sensitivity of Hb Zürich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro.
    Virshup DM, Zinkham WH, Sirota RL, Caughey WS.
    Am J Hematol; 1983 Jun; 14(4):315-24. PubMed ID: 6859031
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hemoglobin Hammersmith (beta 42 (CD1) Phe replaced by Ser) associated with severe hemolytic anemia.
    Rahbar S, Feagler RJ, Beutler E.
    Hemoglobin; 1981 Jun; 5(1):97-105. PubMed ID: 6259091
    [Abstract] [Full Text] [Related]

  • 13. Successful Treatment of a Child with Hemoglobin Hammersmith with Hematopoietic Stem Cell Transplantation.
    Yıldırım AT, Gülen H, Türkmen H, Özek G, Oymak Y, Durmaz B, Karaca E.
    Hemoglobin; 2023 Nov; 47(4):137-139. PubMed ID: 37605549
    [Abstract] [Full Text] [Related]

  • 14. The role of hemoglobin heme loss in Heinz body formation: studies with a partially heme-deficient hemoglobin and with genetically unstable hemoglobins.
    Jacob HS, Winterhalter KH.
    J Clin Invest; 1970 Nov; 49(11):2008-16. PubMed ID: 5475984
    [Abstract] [Full Text] [Related]

  • 15. Hb Volga or alpha 2 beta 2 27(B9)Ala----Asp in an Italian family.
    Sciarratta GV, Ivaldi G, Sansone G, Wilson JB, Webber BB, Huisman TH.
    Hemoglobin; 1985 Nov; 9(1):91-3. PubMed ID: 3838977
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hemoglobin Lufkin: beta 29 (B11) Gly replaced by Asp. An unstable hemoglobin variant involving an internal amino acid residue.
    Schmidt RM, Bechtel KC, Johnson MH, Therrell BL, Moo-Penn WF.
    Hemoglobin; 1977 Nov; 1(8):799-814. PubMed ID: 24022
    [Abstract] [Full Text] [Related]

  • 18. Hb Hammersmith [beta 42(CD1) Phe-->Ser]: occurrence as a de novo mutation in black monozygotic twins with multiple congenital anomalies.
    Tuohy AM, McKie VC, Sabio H, Kutlar F, Kutlar A, Wilson JB.
    J Pediatr Hematol Oncol; 1998 Nov; 20(6):563-6. PubMed ID: 9856680
    [Abstract] [Full Text] [Related]

  • 19. Hemoglobin saitama or beta 117 (G19) His leads to Pro, a new variant causing hemolytic disease.
    Ohba Y, Hasegawa Y, Amino H, Miwa S, Nakatsuji T, Hattori Y, Miyaji T.
    Hemoglobin; 1983 Nov; 7(1):47-56. PubMed ID: 6687721
    [Abstract] [Full Text] [Related]

  • 20. Altered sulfhydryl reactivity of hemoglobins and red blood cell membranes in congenital Heinz body hemolytic anemia.
    Jacob HS, Brain MC, Dacie JV.
    J Clin Invest; 1968 Dec; 47(12):2664-77. PubMed ID: 5725279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.